Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 76.8%
by Teresa Graham · The Cerbat GemMDxHealth SA (NASDAQ:MDXH – Get Free Report) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 106,013 shares, a decline of 76.8% from the May 31st total of 457,830 shares. Based on an average trading volume of 796,277 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company’s stock are short sold.
Institutional Investors Weigh In On MDxHealth
A number of hedge funds have recently added to or reduced their stakes in MDXH. Intesa Sanpaolo Wealth Management purchased a new position in shares of MDxHealth in the 4th quarter worth $36,000. Lido Advisors LLC purchased a new stake in MDxHealth during the third quarter valued at $48,000. GSA Capital Partners LLP purchased a new stake in MDxHealth during the third quarter valued at $48,000. Squarepoint Ops LLC bought a new position in MDxHealth in the fourth quarter valued at about $51,000. Finally, Jefferies Financial Group Inc. bought a new position in MDxHealth in the third quarter valued at about $53,000.
MDxHealth Stock Performance
Shares of NASDAQ:MDXH opened at $0.43 on Friday. The firm has a market cap of $21.13 million, a price-to-earnings ratio of -0.66 and a beta of 1.36. The business has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $2.52. MDxHealth has a fifty-two week low of $0.42 and a fifty-two week high of $5.33.
MDxHealth (NASDAQ:MDXH – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%.The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million. As a group, research analysts predict that MDxHealth will post -0.6 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. BTIG Research dropped their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Lake Street Capital reduced their price target on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.62.
Check Out Our Latest Stock Analysis on MDxHealth
MDxHealth Company Profile
MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.
MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.